Loading Events

« All Events

  • This event has passed.

LifeSciences BC Blakes Breakfast Speaking Event on Bio Pharma

March 8 @ 7:30 AM - 9:30 AM

 

This Breakfast Speaking Series is proudly presented by:

Blakes

LifeSciences BC is pleased to announce our January Blakes Breakfast Speaking Event on Bio Pharma for Wednesday, March 8, 2017.

– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –

The Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. Held four times a year, these breakfasts include presentations by local, national and multinational life science companies and typically attract a cross-section of approximately 40 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake, Cassels & Graydon LLP.

 

Featuring:

Arbutus   vida

 

Company Profiles:

  • Arbutus Biopharma is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

    In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

  • Sepset Biosciences, a CDRD spin-off company, is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Sepset’s blood-based test works by detecting a unique biomarker signature based on the body’s immune response rather than the presence of a pathogen. The results of initial clinical studies show this to be a very promising approach and the company is now in the process of advancing to larger multi-centre, multi-country trials.

  • viDA Therapeutics is advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B (GzmB), to treat autoimmune and chronic inflammatory diseases.  The company is focused on advancing their lead candidate into the clinic for the treatment of the orphan disease, Discoid Lupus Erythematosus (DLE), a chronic inflammatory autoimmune skin disorder. Based on preclinical studies with our topically formulated lead compound VTI-1002, the company is planning to file an Investigational New Drug (IND) application with the FDA within the next 12 months

 

Speaker Profiles:

Peter Lutwyche Peter Lutwyche PhD, Chief Technology Officer, Arbutus Biopharma

Dr. Peter Lutwyche serves as Arbutus’ Chief Technology Officer. Dr. Lutwyche’s responsibilities at Arbutus include manufacturing, process development and quality control for all Arbutus product candidates, as well as supporting Arbutus’ collaborative partners as they advance products that utilize Arbutus’s technology. Previously Dr. Lutwyche was Director, Pharmaceutical Development at QLT Inc. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous pre-clinical and clinical stage products. Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.

 

Jonathon JafariJon Jafari, Senior Director of Business Development, The Centre for Drug Research and Development (CDRD)

Jonathon Jafari is the Senior Director of Business Development at CDRD, where he has been involved in many of CDRD’s startups, including Kairos Therapeutics (which was sold to Zymeworks), Sitka Biopharma, and Zucara. In addition he is the Chief Business Officer and interim Chief Executive Officer for Sepset Biosciences. Prior to joining CDRD, he spent eight years in progressive business development and strategic marketing roles at QLT Inc. Prior to QLT, Mr. Jafari worked for Eli Lilly in the Business Development Market Assessment group and provided market evaluations and sales forecasts for licensing and M&A opportunities.   Mr. Jafari also had research roles at Indiana University in molecular evolution and in tumor targeting at Genetic Therapy Inc., which was a gene therapy company that was acquired by Sandoz, now Novartis.

 

Event Details:

Date: Wednesday, March 8, 2017

Time:
 7:30 – 8:00 AM– Registration and Hot Breakfast
 8:00 – 9:00 AM – Presentations
 9:00 – 9:30 AM – Networking Opportunity

Location: Terminal City Club – 837 West Hastings Street, Vancouver

Registration:

 

*No refunds given within 72 hours of event start.

_______________________________________________________

For more information, please contact:

Irma Zukic
Administrative Coordinator
LifeSciences BC
Tel: 604-669-9909 ext. 1 │ Email: izukic@lifesciencesbc.ca

Details

Date:
March 8
Time:
7:30 AM - 9:30 AM
Event Category:

Organizer

LifeSciences BC

Venue

Terminal City Club
837 West Hastings Street
Vancouver,
+ Google Map